A phase II study of infusional 5-fluorouracil and low-dose leucovorin with docetaxel for advanced gastric cancer

Hei Cheul Jeung, SunYoung Rha, Tae Kim Yong, Hoon Noh Sung, Kyung Roh Jae, Hyuncheol Chung

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: The standard chemotherapy regimen for advanced gastric cancer has not yet been established. We investigated the efficacy and the safety of the combination of docetaxel with infusional 5-fluorouracil (5-FU) and leucovorin (FLT) in advanced gastric cancer. Methods: Patients received docetaxel 75 mg/m 2 (1-hour infusion) followed by a leucovorin bolus 20 mg/m 2 and a 24-hour infusion of 5-FU 1,000 mg/m 2 (day 1-3) every 3 weeks. The response was evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria, and the toxicity was evaluated by National Cancer Institute common toxicity criteria (NCI-CTC). Results: Sixty-six patients were enrolled. Median relative dose intensity was 86%. Of 57 evaluable patients, the overall response rate was 25.7%. The response rate was 34.2% in chemonaïve patients and 14.2% in the patients who had previously received treatment. Median time to progression and overall survival duration were 5.2 and 9.7 months, respectively. The most frequent grade 3-4 toxicity was neutropenia, which was the major cause of treatment delay. Other hematological and nonhematological toxicities were rare. Conclusions: The FLT regimen showed a comparable efficacy with other second-generation regimens. Because of the low nonhematological toxicity, this could be a potential alternative to the cisplatin-containing regimens in gastric cancer.

Original languageEnglish
Pages (from-to)63-70
Number of pages8
JournalOncology
Volume70
Issue number1
DOIs
Publication statusPublished - 2006 Mar 1

Fingerprint

docetaxel
Leucovorin
Fluorouracil
Stomach Neoplasms
National Cancer Institute (U.S.)
Neutropenia
Cisplatin
Safety
Drug Therapy
Survival

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Jeung, Hei Cheul ; Rha, SunYoung ; Yong, Tae Kim ; Sung, Hoon Noh ; Jae, Kyung Roh ; Chung, Hyuncheol. / A phase II study of infusional 5-fluorouracil and low-dose leucovorin with docetaxel for advanced gastric cancer. In: Oncology. 2006 ; Vol. 70, No. 1. pp. 63-70.
@article{59bc1e653c6a414ea52a014fa35c5004,
title = "A phase II study of infusional 5-fluorouracil and low-dose leucovorin with docetaxel for advanced gastric cancer",
abstract = "Background: The standard chemotherapy regimen for advanced gastric cancer has not yet been established. We investigated the efficacy and the safety of the combination of docetaxel with infusional 5-fluorouracil (5-FU) and leucovorin (FLT) in advanced gastric cancer. Methods: Patients received docetaxel 75 mg/m 2 (1-hour infusion) followed by a leucovorin bolus 20 mg/m 2 and a 24-hour infusion of 5-FU 1,000 mg/m 2 (day 1-3) every 3 weeks. The response was evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria, and the toxicity was evaluated by National Cancer Institute common toxicity criteria (NCI-CTC). Results: Sixty-six patients were enrolled. Median relative dose intensity was 86{\%}. Of 57 evaluable patients, the overall response rate was 25.7{\%}. The response rate was 34.2{\%} in chemona{\"i}ve patients and 14.2{\%} in the patients who had previously received treatment. Median time to progression and overall survival duration were 5.2 and 9.7 months, respectively. The most frequent grade 3-4 toxicity was neutropenia, which was the major cause of treatment delay. Other hematological and nonhematological toxicities were rare. Conclusions: The FLT regimen showed a comparable efficacy with other second-generation regimens. Because of the low nonhematological toxicity, this could be a potential alternative to the cisplatin-containing regimens in gastric cancer.",
author = "Jeung, {Hei Cheul} and SunYoung Rha and Yong, {Tae Kim} and Sung, {Hoon Noh} and Jae, {Kyung Roh} and Hyuncheol Chung",
year = "2006",
month = "3",
day = "1",
doi = "10.1159/000091186",
language = "English",
volume = "70",
pages = "63--70",
journal = "Oncology",
issn = "0030-2414",
publisher = "S. Karger AG",
number = "1",

}

A phase II study of infusional 5-fluorouracil and low-dose leucovorin with docetaxel for advanced gastric cancer. / Jeung, Hei Cheul; Rha, SunYoung; Yong, Tae Kim; Sung, Hoon Noh; Jae, Kyung Roh; Chung, Hyuncheol.

In: Oncology, Vol. 70, No. 1, 01.03.2006, p. 63-70.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A phase II study of infusional 5-fluorouracil and low-dose leucovorin with docetaxel for advanced gastric cancer

AU - Jeung, Hei Cheul

AU - Rha, SunYoung

AU - Yong, Tae Kim

AU - Sung, Hoon Noh

AU - Jae, Kyung Roh

AU - Chung, Hyuncheol

PY - 2006/3/1

Y1 - 2006/3/1

N2 - Background: The standard chemotherapy regimen for advanced gastric cancer has not yet been established. We investigated the efficacy and the safety of the combination of docetaxel with infusional 5-fluorouracil (5-FU) and leucovorin (FLT) in advanced gastric cancer. Methods: Patients received docetaxel 75 mg/m 2 (1-hour infusion) followed by a leucovorin bolus 20 mg/m 2 and a 24-hour infusion of 5-FU 1,000 mg/m 2 (day 1-3) every 3 weeks. The response was evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria, and the toxicity was evaluated by National Cancer Institute common toxicity criteria (NCI-CTC). Results: Sixty-six patients were enrolled. Median relative dose intensity was 86%. Of 57 evaluable patients, the overall response rate was 25.7%. The response rate was 34.2% in chemonaïve patients and 14.2% in the patients who had previously received treatment. Median time to progression and overall survival duration were 5.2 and 9.7 months, respectively. The most frequent grade 3-4 toxicity was neutropenia, which was the major cause of treatment delay. Other hematological and nonhematological toxicities were rare. Conclusions: The FLT regimen showed a comparable efficacy with other second-generation regimens. Because of the low nonhematological toxicity, this could be a potential alternative to the cisplatin-containing regimens in gastric cancer.

AB - Background: The standard chemotherapy regimen for advanced gastric cancer has not yet been established. We investigated the efficacy and the safety of the combination of docetaxel with infusional 5-fluorouracil (5-FU) and leucovorin (FLT) in advanced gastric cancer. Methods: Patients received docetaxel 75 mg/m 2 (1-hour infusion) followed by a leucovorin bolus 20 mg/m 2 and a 24-hour infusion of 5-FU 1,000 mg/m 2 (day 1-3) every 3 weeks. The response was evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria, and the toxicity was evaluated by National Cancer Institute common toxicity criteria (NCI-CTC). Results: Sixty-six patients were enrolled. Median relative dose intensity was 86%. Of 57 evaluable patients, the overall response rate was 25.7%. The response rate was 34.2% in chemonaïve patients and 14.2% in the patients who had previously received treatment. Median time to progression and overall survival duration were 5.2 and 9.7 months, respectively. The most frequent grade 3-4 toxicity was neutropenia, which was the major cause of treatment delay. Other hematological and nonhematological toxicities were rare. Conclusions: The FLT regimen showed a comparable efficacy with other second-generation regimens. Because of the low nonhematological toxicity, this could be a potential alternative to the cisplatin-containing regimens in gastric cancer.

UR - http://www.scopus.com/inward/record.url?scp=33644890749&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644890749&partnerID=8YFLogxK

U2 - 10.1159/000091186

DO - 10.1159/000091186

M3 - Article

VL - 70

SP - 63

EP - 70

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 1

ER -